Login to Your Account

Medivir, Boehringer Ingelheim Enter Potential EUR122M Alliance

By Cormac Sheridan

Wednesday, July 16, 2003
As he put it himself, Medivir AB CEO Lars Adlersson had "two reasons to celebrate" Tuesday. The drug discovery company he leads had just signed its largest deal ever, a pact potentially worth €122 million with Boehringer Ingelheim GmbH to develop its candidate HIV drug MIV-310. It was also his 39th birthday. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription